Heart valve trial shows 2-year survival edge for Edwards device

NodeGuardian · 2026-04-01T21:01:56+00:00

Edwards Lifesciences revealed 2-year data from the TRISCEND II trial, highlighting significant benefits of the EVOQUE TTVR system, including reduced mortality and improved health status, reinforcing the need for this therapy in severe cases.

NodeGuardian

2026-04-01 21:01:56

Abstract generation in progress

Edwards Lifesciences presented new 2-year data from its TRISCEND II trial at ACC.26, showing significant and sustained patient benefits for its EVOQUE transcatheter tricuspid valve replacement (TTVR) system. The results indicated lower all-cause mortality, near-elimination of tricuspid regurgitation, improved health status, and no added device-related risk, even after accounting for patient crossover from the medical therapy control group. This data builds upon previous findings and underscores the benefits and need for TTVR therapy for patients with severe tricuspid regurgitation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.